Skip to main content
SpringerLink
Log in

Humanized Mouse and Rat PDX Cancer Models

  • Chapter
  • First Online:
Patient-Derived Xenograft Models of Human Cancer

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

  • 800 Accesses

Abstract

Oncology drug and therapeutic developments are hindered by lack of appropriate preclinical models that faithfully recapitulate tumor pathology, tumor growth and metastasis, genetics, and the tumor microenvironment. In particular, in vitro modeling of tumors often results in a cell line that differs from the patient’s tumor in key genetic aspects directly relating to the cancer phenotype and which thus differs in response to various treatments. Immunodeficient mice have paved the way for in vivo modeling of tumors and disseminated cancers. Growth kinetics and response to therapeutics can be more appropriately modeled in these systems. In addition, the advent of patient-derived xenografts (PDXs), whereby a piece of tumor is taken directly from the patient and grown in the mouse, demonstrates that personalized cancer treatments could be the standard of care. Recent advances in genetically modified rats provide another platform for modeling human cancer and PDX tissues. The rat offers a number of advantages over the mouse, including easier surgical manipulation, larger tumor size and greater blood volume for downstream analyses, as well as being the preferred model for drug efficacy and toxicology studies. This chapter reviews advances in human PDX modeling in the mouse and rat.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

FSG:

F344-scid gamma

GFP:

Green fluorescent protein

NK:

Natural killer

NOD:

Nonobese diabetic

NSG:

NOD scid gamma

PDTX:

Patient-derived tumor xenograft

PDX:

Patient-derived xenograft

SCID:

Severe combined immunodeficiency

References

  1. Cancer Types. National Cancer Institute. https://www.cancer.gov/types. Accessed 21 Nov 2016.

  2. Katt ME, Placone AL, Wong AD, Xu ZS, Searson PC. In vitro tumor models: advantages, disadvantages, variables, and selecting the right platform. Front Bioeng Biotechnol. 2016;4:12. doi:10.3389/fbioe.2016.00012.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Xu X, Farach-Carson MC, Jia X. Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol Adv. 2014;32(7):1256–68. doi:10.1016/j.biotechadv.2014.07.009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Zanoni M, Piccinini F, Arienti C, Zamagni A, Santi S, Polico R, et al. 3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained. Sci Rep. 2016;6:19103. doi:10.1038/srep19103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 2014;344(1):1–12. doi:10.1016/j.canlet.2013.10.010.

    Article  CAS  PubMed  Google Scholar 

  6. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174(10):6477–89.

    Article  CAS  PubMed  Google Scholar 

  7. Strowig T, Rongvaux A, Rathinam C, Takizawa H, Borsotti C, Philbrick W, et al. Transgenic expression of human signal regulatory protein alpha in Rag2-/-gamma(c)-/- mice improves engraftment of human hematopoietic cells in humanized mice. Proc Natl Acad Sci U S A. 2011;108(32):13218–23. doi:10.1073/pnas.1109769108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Takenaka K, Prasolava TK, Wang JC, Mortin-Toth SM, Khalouei S, Gan OI, et al. Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol. 2007;8(12):1313–23. doi:10.1038/ni1527.

    Article  CAS  PubMed  Google Scholar 

  9. Theocharides AP, Rongvaux A, Fritsch K, Flavell RA, Manz MG. Humanized hemato-lymphoid system mice. Haematologica. 2016;101(1):5–19. doi:10.3324/haematol.2014.115212.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Waern JM, Yuan Q, Rudrich U, Becker PD, Schulze K, Strick-Marchand H, et al. Ectopic expression of murine CD47 minimizes macrophage rejection of human hepatocyte xenografts in immunodeficient mice. Hepatology. 2012;56(4):1479–88. doi:10.1002/hep.25816.

    Article  CAS  PubMed  Google Scholar 

  11. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100(9):3175–82.

    Article  CAS  PubMed  Google Scholar 

  12. Flanagan SP. ‘Nude’, a new hairless gene with pleiotropic effects in the mouse. Genet Res. 1966;8(3):295–309.

    Article  CAS  PubMed  Google Scholar 

  13. Falk I, Potocnik AJ, Barthlott T, Levelt CN, Eichmann K. Immature T cells in peripheral lymphoid organs of recombinase-activating gene-1/-2-deficient mice. Thymus dependence and responsiveness to anti-CD3 epsilon antibody. J Immunol. 1996;156(4):1362–8.

    CAS  PubMed  Google Scholar 

  14. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 1992;68(5):869–77.

    Article  CAS  PubMed  Google Scholar 

  15. Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992;68(5):855–67.

    Article  CAS  PubMed  Google Scholar 

  16. Nonoyama S, Smith FO, Bernstein ID, Ochs HD. Strain-dependent leakiness of mice with severe combined immune deficiency. J Immunol. 1993;150(9):3817–24.

    CAS  PubMed  Google Scholar 

  17. Richmond A, Su Y. Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 2008;1(2–3):78–82. doi:10.1242/dmm.000976.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Hutchinson L, Kirk R. High drug attrition rates—where are we going wrong? Nat Rev Clin Oncol. 2011;8(4):189–90. doi:10.1038/nrclinonc.2011.34.

    Article  PubMed  Google Scholar 

  19. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007;2(2):247–50. doi:10.1038/nprot.2007.25.

    Article  CAS  PubMed  Google Scholar 

  20. Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol. 2010;12(7):473–80. doi:10.1007/s12094-010-0540-6.

    Article  PubMed  Google Scholar 

  21. Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, et al. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res. 2006;12(13):4043–54. doi:10.1158/1078-0432.CCR-06-0252.

    Article  CAS  PubMed  Google Scholar 

  22. Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models. Nat Rev Cancer. 2015;15(5):311–6. doi:10.1038/nrc3944.

    Article  CAS  PubMed  Google Scholar 

  23. Dong X, Guan J, English JC, Flint J, Yee J, Evans K, et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin Cancer Res. 2010;16(5):1442–51. doi:10.1158/1078-0432.CCR-09-2878.

    Article  CAS  PubMed  Google Scholar 

  24. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4(9):998–1013. doi:10.1158/2159-8290.CD-14-0001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9(6):338–50. doi:10.1038/nrclinonc.2012.61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Lee JY, Kim SY, Park C, Kim NK, Jang J, Park K, et al. Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget. 2015;6(28):25619–30. doi:10.18632/oncotarget.4627.

    Article  PubMed  PubMed Central  Google Scholar 

  27. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17(11):1514–20. doi:10.1038/nm.2454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res. 2008;14(20):6456–68. doi:10.1158/1078-0432.CCR-08-0138.

    Article  CAS  PubMed  Google Scholar 

  29. Bankert RB, Balu-Iyer SV, Odunsi K, Shultz LD, Kelleher Jr RJ, Barnas JL, et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One. 2011;6(9):e24420. doi:10.1371/journal.pone.0024420.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Krumbach R, Schuler J, Hofmann M, Giesemann T, Fiebig HH, Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer. 2011;47(8):1231–43. doi:10.1016/j.ejca.2010.12.019.

    Article  CAS  PubMed  Google Scholar 

  31. Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ, et al. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol. 2011;59(4):619–28. doi:10.1016/j.eururo.2010.11.043.

    Article  PubMed  Google Scholar 

  32. Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, et al. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Investig New Drugs. 2012;30(6):2391–9. doi:10.1007/s10637-012-9818-6.

    Article  CAS  Google Scholar 

  33. Morton JJ, Bird G, Refaeli Y, Jimeno A. Humanized mouse xenograft models: narrowing the tumor-microenvironment gap. Cancer Res. 2016;76(21):6153–8. doi:10.1158/0008-5472.CAN-16-1260.

    Article  CAS  PubMed  Google Scholar 

  34. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol. 2012;12(11):786–98. doi:10.1038/nri3311.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Muenst S, Laubli H, Soysal SD, Zippelius A, Tzankov A, Hoeller S. The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med. 2016;279(6):541–62. doi:10.1111/joim.12470.

    Article  CAS  PubMed  Google Scholar 

  36. McMillin DW, Negri JM, Mitsiades CS. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov. 2013;12(3):217–28. doi:10.1038/nrd3870.

    Article  CAS  PubMed  Google Scholar 

  37. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012;18(9):1359–68. doi:10.1038/nm.2890.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13(6):394. doi:10.1038/nrclinonc.2016.65.

    Article  CAS  PubMed  Google Scholar 

  39. Vudattu NK, Waldron-Lynch F, Truman LA, Deng S, Preston-Hurlburt P, Torres R, et al. Humanized mice as a model for aberrant responses in human T cell immunotherapy. J Immunol. 2014;193(2):587–96. doi:10.4049/jimmunol.1302455.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Hougen HP. The athymic nude rat. Immunobiological characteristics with special reference to establishment of non-antigen-specific T-cell reactivity and induction of antigen-specific immunity. APMIS Suppl. 1991;21:1–39.

    CAS  PubMed  Google Scholar 

  41. Hougen HP, Klausen B. Effects of homozygosity of the nude (rnu) gene in an inbred strain of rats: studies of lymphoid and non-lymphoid organs in different age groups of nude rats of LEW background at a stage in the gene transfer. Lab Anim. 1984;18(1):7–14.

    Article  CAS  PubMed  Google Scholar 

  42. Jaenisch R, Mintz B. Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. Proc Natl Acad Sci U S A. 1974;71(4):1250–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Buehr M, Meek S, Blair K, Yang J, Ure J, Silva J, et al. Capture of authentic embryonic stem cells from rat blastocysts. Cell. 2008;135(7):1287–98. doi:10.1016/j.cell.2008.12.007.

    Article  CAS  PubMed  Google Scholar 

  44. Li P, Tong C, Mehrian-Shai R, Jia L, Wu N, Yan Y, et al. Germline competent embryonic stem cells derived from rat blastocysts. Cell. 2008;135(7):1299–310. doi:10.1016/j.cell.2008.12.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ivics Z, Izsvak Z, Medrano G, Chapman KM, Hamra FK. Sleeping beauty transposon mutagenesis in rat spermatogonial stem cells. Nat Protoc. 2011;6(10):1521–35. doi:10.1038/nprot.2011.378.

    Article  CAS  PubMed  Google Scholar 

  46. Izsvak Z, Frohlich J, Grabundzija I, Shirley JR, Powell HM, Chapman KM, et al. Generating knockout rats by transposon mutagenesis in spermatogonial stem cells. Nat Methods. 2010;7(6):443–5. doi:10.1038/nmeth.1461.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Chapman KM, Medrano GA, Jaichander P, Chaudhary J, Waits AE, Nobrega MA, et al. Targeted germline modifications in rats using CRISPR/Cas9 and spermatogonial stem cells. Cell Rep. 2015;10(11):1828–35. doi:10.1016/j.celrep.2015.02.040.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Hamra FK, Chapman KM, Nguyen DM, Williams-Stephens AA, Hammer RE, Garbers DL. Self-renewal, expansion, and transfection of rat spermatogonial stem cells in culture. Proc Natl Acad Sci U S A. 2005;102(48):17430–5. doi:10.1073/pnas.0508780102.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Hamra FK, Chapman KM, Wu Z, Garbers DL. Isolating highly pure rat spermatogonial stem cells in culture. Methods Mol Biol. 2008;450:163–79. doi:10.1007/978-1-60327-214-8_12.

    Article  CAS  PubMed  Google Scholar 

  50. Tsuchida T, Zheng YW, Zhang RR, Takebe T, Ueno Y, Sekine K, et al. The development of humanized liver with Rag1 knockout rats. Transplant Proc. 2014;46(4):1191–3. doi:10.1016/j.transproceed.2013.12.026.

    Article  CAS  PubMed  Google Scholar 

  51. Mashimo T, Takizawa A, Kobayashi J, Kunihiro Y, Yoshimi K, Ishida S, et al. Generation and characterization of severe combined immunodeficiency rats. Cell Rep. 2012;2(3):685–94. doi:10.1016/j.celrep.2012.08.009.

    Article  CAS  PubMed  Google Scholar 

  52. Kuijk EW, Rasmussen S, Blokzijl F, Huch M, Gehart H, Toonen P, et al. Generation and characterization of rat liver stem cell lines and their engraftment in a rat model of liver failure. Sci Rep. 2016;6:22154. doi:10.1038/srep22154.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Mashimo T, Takizawa A, Voigt B, Yoshimi K, Hiai H, Kuramoto T, et al. Generation of knockout rats with X-linked severe combined immunodeficiency (X-SCID) using zinc-finger nucleases. PLoS One. 2010;5(1):e8870. doi:10.1371/journal.pone.0008870.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Colston MJ, Fieldsteel AH, Dawson PJ. Growth and regression of human tumor cell lines in congenitally athymic (rnu/rnu) rats. J Natl Cancer Inst. 1981;66(5):843–8.

    CAS  PubMed  Google Scholar 

  55. Maruo K, Ueyama Y, Kuwahara Y, Hioki K, Saito M, Nomura T, et al. Human tumour xenografts in athymic rats and their age dependence. Br J Cancer. 1982;45(5):786–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, Tajbakhsh M, et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood. 2002;99(11):4100–8.

    Article  CAS  PubMed  Google Scholar 

  57. Patel B, Dey A, Castleton AZ, Schwab C, Samuel E, Sivakumaran J, et al. Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology. Blood. 2014;124(1):96–105. doi:10.1182/blood-2014-01-549352.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hera BioLabs, Inc., 2277 Thunderstick Dr. #500, Lexington, KY, 40505, USA

    Fallon K. Noto & Tseten Yeshi

Authors
  1. Fallon K. Noto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tseten Yeshi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fallon K. Noto .

Editor information

Editors and Affiliations

  1. Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada

    Yuzhuo Wang

  2. Department of Experimental Therapeutics, BC Cancer Research Centre, Vancouver, British Columbia, Canada

    Dong Lin

  3. Living Tumor Laboratory, BC Cancer Agency/Vancouver Prostate Centre, Vancouver, British Columbia, Canada

    Peter W. Gout

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Noto, F.K., Yeshi, T. (2017). Humanized Mouse and Rat PDX Cancer Models. In: Wang, Y., Lin, D., Gout, P. (eds) Patient-Derived Xenograft Models of Human Cancer . Molecular and Translational Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-55825-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-55825-7_4

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-55824-0

  • Online ISBN: 978-3-319-55825-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation